Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Juno Therapeutics
Biotech
Indapta snags $50M and signs on former Juno exec as CEO
Indapta raised more than $50 million in series A financing and has tapped former Juno Therapeutics exec Mark Frohlich, M.D., to be its new CEO.
Max Bayer
Feb 10, 2022 7:30am
Poseida shares plunge after death in solid tumor CAR-T trial
Aug 18, 2020 7:15am
Natural killer biotech Artiva launches with $78M
Jun 26, 2020 8:30am
Juno-lite Sana raises $700M
Jun 23, 2020 8:15am
Juno-WuXi AppTec JV JW Therapeutics nabs $100M for cell therapy
Jun 11, 2020 8:05am
FDA delays decision on approval of Bristol Myers' CAR-T
May 6, 2020 8:10am
